Osteoclast inhibitors for knee conditions
View Patent ↗Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
1. A method of treating a bone marrow lesion of the knee comprising: selecting a patient having a bone marrow lesion of the knee and OARS Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, and administering an inhibitor of osteoclast activity selected from zoledronic acid, pamidronic acid, or neridronic acid to the patient for the treatment of the bone marrow lesion.
2. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice.
3. The method of claim 2 , wherein the inhibitor of osteoclast activity is administered about every three months, or more frequently.
4. The method of claim 1 , wherein the inhibitor of osteoclast activity is zoledronic acid.
5. The method of claim 1 , wherein the inhibitor of osteoclast activity is pamidronic acid.
6. The method of claim 1 , wherein the inhibitor of osteoclast activity is neridronic acid.
7. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered orally.
8. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered intravenously.
9. The method of claim 1 , wherein the patient experiences a reduction in bone marrow lesion size that is at least about 15% within about 6 months after the inhibitor of osteoclast activity is administered to the patient.
10. The method of claim 1 , wherein the patient experiences a reduction in bone marrow lesion size that is at least about 25% within about 6 months after the inhibitor of osteoclast activity is administered to the patient.
11. The method of claim 2 , wherein the inhibitor of osteoclast activity is administered at least twice over a period of at least four weeks.
12. The method of claim 9 , wherein the inhibitor of osteoclast activity is administered once weekly for a period of six weeks.
13. The method of claim 10 , wherein the inhibitor of osteoclast activity comprises zoledronic acid, and the weekly dose is between about 25 mg and about 75 mg.